Discovery Labs fell after reporting its fourth-quarter results. Is this dip a buying opportunity or a cue to keep your distance?
News & Analysis: Discovery Laboratories
Shares of Discovery Labs jumped almost 40% on Friday. Find out what it means for the company as well as drug giant AbbVie and fellow specialty biotech Cornerstone Therapeutics.
The company aims to raise net proceeds of more than $13 million in the issue.
This company is king when it comes to drug delays.
Let's look forward to this company's next earnings report.
Chairman and CEO W. Thomas Amick retires; board reduced from six to five members.
A little light could help investors immensely.
Stifel Nicolaus wades back into biotech, with four big buy ratings.